Journal of Drug Development and Clinical Therapeutics

WEARABLE TECHNOLOGIES IN CLINICAL TRIALS FOR DRUG DEVELOPMENT: TRENDS AND EMERGING OPPORTUNITIES

Sadhana Kanukuntla — Fri, 15 May 2026 00:00:00 -0400

Wearable technologies have emerged as transformative tools in modern clinical trials and pharmaceutical drug development by enabling continuous physiological monitoring, remote patient assessment, real-time data collection, and decentralized clinical research. Conventional clinical trial methodologies frequently encounter challenges including limited patient engagement, poor adherence, geographic restrictions, delayed data acquisition, and high operational costs. The integration of wearable devices into clinical research environments has significantly improved patient monitoring capabilities, data accuracy, therapeutic assessment, and healthcare accessibility.Wearable technologies include smartwatches, biosensors, fitness trackers, electrocardiographic monitors, glucose monitoring systems, wearable patches, and implantable monitoring devices capable of measuring physiological parameters such as heart rate, sleep quality, physical activity, blood glucose, oxygen saturation, temperature, and neurological responses. These technologies support remote monitoring and real-world evidence generation during drug development processes.Artificial intelligence, cloud computing, machine learning, wireless communication systems, and mobile health applications further enhance the analytical capabilities of wearable technologies by enabling predictive analytics, automated alerts, and personalized healthcare insights. Pharmaceutical companies increasingly utilize wearable systems in decentralized clinical trials to improve participant retention, treatment adherence, and real-time safety surveillance.Pharmacists contribute significantly to wearable-assisted clinical research through medication therapy management, patient counseling, adherence monitoring, pharmacovigilance, and data interpretation. Collaborative integration between pharmacists, clinicians, biomedical engineers, and data scientists supports optimized therapeutic outcomes and evidence-based clinical decision-making.Despite substantial benefits, important challenges remain regarding regulatory compliance, cybersecurity, patient privacy, device accuracy, data standardization, interoperability, and ethical considerations. This manuscript explores the evolution, technologies, applications, pharmacist interventions, benefits, limitations, ethical concerns, statistical trends, and future opportunities of wearable technologies in clinical trials and pharmaceutical drug development.

RECENT ADVANCES IN MICROFLUIDICS FOR THE PREPARATION OF DRUG AND GENE DELIVERY SYSTEMS

J Bhargava Narendra — Fri, 15 May 2026 00:00:00 -0400

Microfluidic technology has emerged as a transformative platform in pharmaceutical sciences for the preparation of advanced drug and gene delivery systems. Conventional nanoparticle fabrication methods frequently encounter limitations such as poor reproducibility, broad particle-size distribution, low encapsulation efficiency, batch-to-batch variation, and inadequate control over physicochemical properties. Microfluidic systems overcome many of these challenges by enabling precise manipulation of microscale fluid dynamics, rapid mixing, controlled nanoprecipitation, and highly reproducible formulation conditions. Recent advances in microfluidic technologies have significantly accelerated the development of lipid nanoparticles, polymeric nanoparticles, liposomes, nanoemulsions, micelles, and nucleic acid delivery systems intended for targeted and personalized therapeutics. Microfluidics-based fabrication techniques provide enhanced control over particle morphology, size distribution, surface characteristics, drug loading, and release kinetics. These systems are particularly valuable in the preparation of gene delivery vehicles including messenger RNA, plasmid DNA, siRNA, and CRISPR-associated delivery platforms. The growing success of mRNA vaccines and nanomedicine has further intensified scientific interest in scalable microfluidic manufacturing systems for pharmaceutical applications. Advances in lab-on-a-chip technologies, artificial intelligence-assisted process optimization, continuous-flow synthesis, and automated pharmaceutical engineering have expanded the clinical and industrial relevance of microfluidic systems. Pharmacists contribute significantly through formulation optimization, medication safety monitoring, therapeutic evaluation, patient counseling, quality assurance, and translational pharmaceutical research. Despite promising progress, important challenges remain regarding industrial scalability, device standardization, manufacturing costs, regulatory approval pathways, and large-scale commercialization. This manuscript discusses recent developments in microfluidic technologies for drug and gene delivery systems, including fabrication techniques, pharmaceutical applications, physicochemical advantages, clinical relevance, pharmacist interventions, regulatory considerations, emerging opportunities, and future perspectives within precision medicine and nanotherapeutic development.

MRNA VACCINE PLATFORM FOR NON-COVID DISEASES: UPDATES IN CANCER, HIV, AND INFLUENZA THERAPEUTICS

Naga Subrahmanyam S — Fri, 15 May 2026 00:00:00 -0400

Messenger RNA (mRNA) vaccine technology has emerged as one of the most transformative biomedical innovations of the twenty-first century, particularly following the global success of mRNA vaccines during the COVID-19 pandemic. Beyond SARS-CoV-2 prevention, mRNA vaccine platforms are increasingly being investigated for numerous non-COVID diseases including cancer, human immunodeficiency virus (HIV), influenza, and other infectious and chronic disorders. Unlike conventional vaccine technologies, mRNA vaccines provide rapid design flexibility, scalable manufacturing, enhanced immunogenicity, and precise antigen targeting while avoiding risks associated with live attenuated pathogens. Advances in lipid nanoparticle delivery systems, nucleoside modifications, computational immunology, and synthetic biology have significantly expanded the therapeutic potential of mRNA-based platforms.Cancer immunotherapy represents one of the most promising applications of mRNA vaccines due to their ability to encode tumor-associated antigens and stimulate adaptive immune responses. Personalized neoantigen-based cancer vaccines are currently under clinical evaluation for melanoma, lung cancer, colorectal cancer, and other malignancies. Similarly, HIV vaccine development has benefited from mRNA technologies capable of generating broadly neutralizing antibodies and enhancing cellular immunity. Influenza vaccine research also increasingly utilizes mRNA systems to improve strain adaptability, immunogenicity, and pandemic preparedness.Pharmacists contribute significantly to mRNA vaccine implementation through medication management, vaccine storage optimization, patient counseling, pharmacovigilance, public health education, and interdisciplinary collaboration. Despite remarkable progress, several challenges remain regarding long-term stability, manufacturing scalability, cold-chain logistics, vaccine hesitancy, regulatory pathways, and equitable global distribution.This manuscript reviews recent updates in mRNA vaccine platforms for non-COVID diseases with emphasis on cancer therapeutics, HIV prevention, influenza vaccines, pharmacist interventions, technological innovations, clinical applications, safety considerations, and future perspectives in precision immunotherapy and global healthcare.

THE RISE OF “PHARMACY DESERTS”: THE IMPACT OF RETAIL DRUGSTORE CLOSURES ON VULNERABLE POPULATIONS AND MEDICATION ACCESSIBILITY

Pallam Narayana Swamy — Fri, 15 May 2026 00:00:00 -0400

The growing phenomenon of “pharmacy deserts” has emerged as a significant public health concern in many countries, particularly within economically disadvantaged and medically underserved communities. Pharmacy deserts refer to geographic regions where residents experience limited or absent access to community pharmacies and essential pharmaceutical services. Recent waves of national retail drugstore closures have intensified healthcare disparities by reducing access to prescription medications, vaccination services, chronic disease management, medication counseling, and preventive healthcare support. Large retail pharmacy chains have increasingly closed outlets due to financial pressures, changing consumer behaviors, competition from online pharmacies, reimbursement challenges, workforce shortages, and evolving healthcare economics. The consequences of pharmacy closures disproportionately affect vulnerable populations including elderly individuals, low-income families, racial and ethnic minorities, rural communities, uninsured populations, and patients with chronic illnesses. Reduced access to nearby pharmacies contributes to medication non-adherence, delayed treatment initiation, worsening chronic disease outcomes, increased emergency department visits, and higher hospitalization rates. Transportation barriers and digital health inequalities further intensify healthcare access limitations among socially disadvantaged populations. Pharmacists continue to play essential roles in addressing medication accessibility challenges through telepharmacy services, mobile pharmacy programs, medication therapy management, patient counseling, vaccination campaigns, and collaborative healthcare initiatives. Technological advancements including mail-order pharmacy systems, digital health platforms, and telemedicine services provide potential solutions to improve pharmaceutical care delivery in underserved regions. Despite emerging innovations, major concerns remain regarding healthcare inequities, regulatory limitations, workforce shortages, reimbursement policies, and sustainability of community pharmacy services. This manuscript explores the causes, epidemiology, social determinants, pharmacist interventions, healthcare consequences, emerging technologies, policy implications, and future strategies associated with the rise of pharmacy deserts and declining medication accessibility among vulnerable populations.

PHARMACOGENOMICS: APPLYING GENETIC TESTING TO OPTIMIZE MEDICATION THERAPY

Sanginidi Indu Harini — Fri, 15 May 2026 00:00:00 -0400

Pharmacogenomics has emerged as a revolutionary field within precision medicine that investigates how genetic variations influence individual responses to medications. Variability in drug efficacy, toxicity, metabolism, and therapeutic outcomes among patients often results from inherited genetic differences affecting pharmacokinetic and pharmacodynamic pathways. Conventional medication prescribing strategies frequently rely on standardized dosing regimens that may not account for patient-specific genetic characteristics, thereby increasing the risk of adverse drug reactions, treatment failure, and healthcare costs. Pharmacogenomic testing offers opportunities to personalize medication therapy by identifying genetic polymorphisms associated with drug metabolism, transport, receptor sensitivity, and enzymatic activity.Advances in genomic sequencing technologies, molecular diagnostics, bioinformatics, and artificial intelligence have accelerated the clinical implementation of pharmacogenomics across multiple therapeutic areas including oncology, cardiology, psychiatry, infectious diseases, pain management, and neurology. Genetic biomarkers involving cytochrome P450 enzymes, human leukocyte antigens, thiopurine methyltransferase, and various transporter proteins now support evidence-based medication selection and dose optimization. Pharmacogenomic-guided therapy improves treatment efficacy, reduces adverse drug reactions, enhances medication adherence, and supports individualized healthcare delivery.Pharmacists play increasingly important roles in pharmacogenomic implementation through genetic test interpretation, medication therapy management, patient counseling, clinical decision support, adverse event prevention, and interdisciplinary collaboration. Despite substantial progress, significant challenges remain regarding clinical integration, healthcare provider education, ethical concerns, cost-effectiveness, reimbursement policies, data privacy, and equitable access to genetic testing servicesThis manuscript discusses the principles, technologies, clinical applications, pharmacist interventions, ethical considerations, implementation challenges, emerging innovations, and future perspectives of pharmacogenomics in optimizing medication therapy and advancing personalized healthcare systems.

; ; ; ; ; ; ; ; ;